Loading
A phase 1/2 trial of Enzalutamide, Abiraterone acetate in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC is a phase 1/2 interventional study registered as NCT07226986 by Novartis Pharmaceuticals, with 123 participants planned, started 2025-12-05 and due to reach its primary completion in 2028-07-10. Interventions recorded: AMO959, AAA617, Enzalutamide, Abiraterone. Conditions listed: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy. No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Enzalutamide, Novartis, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.
Shares Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.